Class Action Alleges CVS Misleadingly Advertises Dosage on Calcium and Glucosamine Supplements

Filed in federal court, the lawsuit claims consumers are misled into believing each individual pill delivers the full advertised dosage, when in reality buyers must take up to three softgels or capsules to get the promised amount.

CVS Supplement Labels Lead to Inflated Prices, Class Action Claims

When you shop for health supplements, you count on bottle labels to be accurate and straightforward. However, a 32-page legal complaint filed on May 26, 2026, alleges that CVS uses front-label real estate to trick buyers searching for high-potency products.

The lawsuit targets two specific CVS store-brand products:

• CVS Calcium 1200 mg + D3

• CVS Glucosamine HCI 1500 mg Chondroitin Sulfate 1200 mg

According to the suit, CVS prominently displays large dosage figures—such as “1200 mg” or “1500 mg”—on the front of the packaging to grab consumer attention. Buyers naturally assume each pill contains that amount. However, fine print on the back reveals that a single Calcium softgel provides only half of the advertised dosage, while a single Glucosamine capsule provides just one-third.

Because shoppers receive a fraction of the expected value per pill, the filing claims everyday consumers have “grossly overpaid” for these products.

High-Dosage Supplement Craze Drives Misleading Packaging Trends

In recent years, consumer demand for high-potency vitamins and joint health supplements has soared. The complaint notes that CVS was among many health and wellness retailers that scrambled to offer high-dosage options to meet market demand.

Rather than formulating capsules that contain higher concentrations of active ingredients, the lawsuit claims CVS chose a shortcut: manufacturing standard lower-dosage pills while using front-label graphics that imply higher potency per unit.

The lawsuit highlights that competitor brands routinely avoid confusing customers. Many rival supplement makers explicitly state on the front label that dosage amounts apply “per 4 caplets” or simply display the exact amount delivered in a single pill.

“Rather than create an actual high-dosage supplement, CVS opted instead to make products with lower dosages, then market them with deceptive labeling and packaging claims,” the lawsuit alleges.

Understanding California Consumer Protection and False Advertising Laws

The legal action, Helen Wittman v. CVS Pharmacy, Inc. (Case No. 5:26-cv-02827), was filed in California federal court. The plaintiff points to key state statutes designed to hold corporations accountable for misleading marketing practices:

• California Unfair Competition Law (UCL): Prohibits unlawful, unfair, or fraudulent business acts and deceptive advertising practices.

• California False Advertising Law (FAL): Outlaws making untrue or misleading statements to induce consumers to purchase products.

• California Consumers Legal Remedies Act (CLRA): Protects shoppers against unfair methods of competition and deceptive business practices.

Under these consumer protection statutes, advertising does not have to be technically false on every panel to be illegal. If a front-label statement creates a likelihood of deception for a reasonable shopper, courts can find the marketing practice unlawful.

Are You Eligible to Join the Proposed CVS Supplement Class Action?

You may be eligible to benefit from this litigation if you purchased select CVS store-brand Calcium or Glucosamine supplements for personal or household use within the applicable statute of limitations period.

Specifically, the lawsuit seeks to represent all U.S. residents who purchased:

• CVS Calcium 1200 mg + D3 softgels

• CVS Glucosamine HCI 1500 mg Chondroitin Sulfate 1200 mg capsules

At this stage, the case is a proposed class action. That means a court must first grant class certification before any formal settlement or financial payout is established.